Close this search box.

J&J data at ASCO probe new target space, toxicity limits for actinium

ARTICLE | Product Development

The radiotherapy is one of multiple modalities J&J is testing against KLK2, which could enable tumor-specific targeting across prostate cancer stages

By Karen Tkach Tuzman, Director of Biopharma Intelligence

May 24, 2024 11:48 PM UTC

As the radiopharmaceutical field shifts its focus to high-potency α particle-emitters, Phase I data from J&J is probing both the promise and the dosing limits of actinium-225, the most widely pursued radioisotope in the class.

The pharma believes the data help validate its target thesis. It is one of few companies pursuing KLK2 for prostate cancer, and the only one with a disclosed radiopharmaceutical against the protein in a field awash with PSMA-targeting agents…